Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with a specific type of blood cancer called CML (chronic myeloid leukemia) in its early stage, known as "chronic phase"
- Your diagnosis was made no more than 3 months (90 days) before joining the trial
- Your diagnosis has been confirmed by specific laboratory tests, including a test for the Philadelphia chromosome
- A specific genetic marker in your blood (called BCR::ABL1) can be detected and measured by a lab test
- You are starting your first-ever treatment for CML using a type of medication called a tyrosine kinase inhibitor (a targeted cancer drug)
- You have not yet received any CML medications (including hydroxyurea) before your first blood sample is taken at diagnosis
- You have signed consent forms for both parts of the study
- You are able to read and understand French
- You are covered by, or a dependent of someone covered by, French social security
Who may not be able to join:
- Your CML is in a more advanced stage, called "accelerated phase" or "blast phase"
- You do not wish to take part in the study
- You have already started treatment before enrolling in the trial
- You are under a legal protection order, guardianship, or have restricted personal freedoms (confirm with trial site)
- You are currently pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marc BERGER, University Hospital, Clermont-Ferrand
Phone: +33473754963
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Biological age determination; Individual fragility assessment; Individual fragility assessment; Tolerance of tyrosine kinase inhibitors; Tolerance of tyrosine kinase inhibitors; Tolerance of tyrosine kinase inhibitors; Tolerance of tyrosine kinase inhibitors; Tolerance of tyrosine kinase inhibitors
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.